NewsAI-assisted

FDA Approves OxiWear's Innovative Ear-Worn Pulse Oximeter for Real-Time Health Monitoring

FDA approves OxiWear's ear-worn pulse oximeter, advancing real-time health monitoring technology.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Aug 30, 2024Updated Jun 26, 2025 · 2 min read
FDA Approves OxiWear's Innovative Ear-Worn Pulse Oximeter for Real-Time Health Monitoring
https://www.sportsbusinessjournal.com/Articles/2023/10/23/oxiwear
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

The U.S. Food and Drug Administration (FDA) has granted approval to OxiWear for its innovative ear-worn pulse oximeter, signaling a significant leap forward in wearable health technology.

This device is designed for continuous, real-time monitoring of blood oxygen saturation (SpO₂) and pulse rate, offering precise and convenient tracking for users, whether they are active or at rest. It is suitable for all skin types and can be used in both clinical and home environments.

The OxiWear device provides uninterrupted oxygen saturation data, which is vital for the early detection of hypoxemia—a condition characterized by low blood oxygen levels. With its emergency messaging alerts, OxiWear's technology holds life-saving potential.

Designed with patient comfort and ease of use in mind, the OxiWear device is lightweight and non-intrusive, allowing for continuous monitoring without disrupting daily activities. It utilizes advanced sensor technology and wireless capabilities to transmit data to healthcare providers, facilitating continuous evaluation and care management.

"This FDA approval highlights the extensive testing and development efforts by our team to meet the highest safety and efficacy standards," said OxiWear CEO Shavini Fernando. "Our aim is to deliver a reliable, user-friendly solution that empowers patients and aids healthcare professionals in providing optimal care."

OxiWear is poised to expand its presence in the health monitoring technology market. The company plans to further its research and development efforts to enhance its platform and address a broader range of health monitoring needs.

Dr. Panagis Galiatsatos, an associate professor at Johns Hopkins University Hospital’s Division of Pulmonary and Critical Care Medicine, emphasized the device's impact, stating, "This device will save lives by detecting life-threatening hypoxemia and preserving the quality of life for patients who need to monitor their oxygen levels."

 

TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →